Wirksamkeit und Kosten der 5-HT3-Antagonisten beim akuten chemotherapieinduzierten Erbrechen
- 1 December 1997
- journal article
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 92 (12) , 747-752
- https://doi.org/10.1007/bf03044673
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesisAnnals of Oncology, 1995
- Dexamethasone, Granisetron, or Both for the Prevention of Nausea and Vomiting during Chemotherapy for CancerNew England Journal of Medicine, 1995
- Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group StudyOncology, 1995
- Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cyclesBritish Journal of Cancer, 1994
- The real costs of emesis—An economic analysis of ondansetron vs. Metoclopramide in controlling emesis in patients receiving chemotherapy for cancerEuropean Journal Of Cancer, 1993
- OndansetronPharmacoEconomics, 1992
- Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group studyBritish Journal of Cancer, 1992
- Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetronEuropean Journal Of Cancer, 1992